Article(id=1329527132511907939, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329527047069741522, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2024.05.011, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1697299200000, receivedDateStr=2023-10-15, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794913569809, onlineDateStr=2026-11-17, pubDate=1715270400000, pubDateStr=2024-05-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794913569809, onlineIssueDateStr=2026-11-17, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794913569809, creator=13701087609, updateTime=1794913569809, updator=13701087609, issue=Issue{id=1329527047069741522, tenantId=1146029695717560320, journalId=1319690329412173987, year='2024', volume='45', issue='5', pageStart='449', pageEnd='566', issueExtLink='null', onlineDate='null', pubDate='1715270400000', pubDateStr='2024-05-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794913549438, creator='13701087609', updateTime=1794962129197, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1329730805833773281, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329527047069741522, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1329730805833773282, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329527047069741522, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=514, endPage=520, ext={EN=ArticleExt(id=1329527132822286437, articleId=1329527132511907939, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Efficacy of durvalumab combined with cisplatin and docetaxel as neoadjuvant therapy in the treatment of locally advanced non-small cell lung cancer patients, columnId=1325221089055486019, journalTitle=World Clinical Drug, columnName=Article, runingTitle=null, highlight=null, articleAbstract=
Objective

To explore the efficacy and safety of durvalumab combined with cisplatin and docetaxel as neoadjuvant therapy in the treatment of locally advanced non-small cell lung cancer (NSCLC) patients.

Methods

This prospective, single-arm clinical study included twenty-five patients with locally advanced NSCLC from January 2020 to March 2021 who received durvalumab combined with cisplatin and docetaxel neoadjuvant therapy for 2 cycles before surgery. Then they received durvalumab monotherapy or combined with cisplatin and docetaxel adjuvant therapy after surgery. After discharge, patients were followed up every 1 to 2 months for the first six months and every 3 to 6 months thereafter. The primary outcome was pathological remission rate. Secondary outcome measures were clinical response rate, disease-free survival (DFS), and overall survival (OS).

Results

The mean age of all enrolled patients was (59.84±7.14) years, including 18 males (72.00%) and 7 females (28.00%). The primary outcome indicated that 56% patients achieved significant pathological response, among which 24% achieved complete pathological response. The secondary outcome showed that 0, 60%, 36% and 4% patients achieved clinical complete response, partial response, disease stability and disease progression, and the overall objective response rate was 60%. The 1-year DFS was 79%, and the 1-year OS was 90%. There was no correlation of Eastern Cooperative Oncology Group performance status and TNM stage with DFS or OS. Besides, The most common adverse events were alopecia (48%), fatigue (40%), nausea and vomiting (36%). Most of the adverse events were at grade 1 to 2, only a few were at grade 3 to 4.

Conclusion

Durvalumab combined with cisplatin and docetaxel exhibits good efficacy profile as neoadjuvant therapy in locally advanced NSCLC patients.

, authors=Xiaozun YANG1, Qiang LI1, 2, *, authorsList=Xiaozun YANG, Qiang LI, authorCompany=null, correspAuthors=Qiang LI, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329527133078138982, articleId=1329527132511907939, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=度伐利尤单抗联合顺铂和多西他赛新辅助治疗局部晚期非小细胞肺癌的疗效评估, columnId=1325221089235841093, journalTitle=世界临床药物, columnName=研究论文, runingTitle=null, highlight=null, articleAbstract=
目的

探索度伐利尤单抗联合顺铂和多西他赛新辅助治疗局部晚期非小细胞肺癌的疗效与安全性。

方法

本前瞻性、单臂临床研究纳入25例2020年1月至2021年3月局部晚期非小细胞肺癌患者,术前接受度伐利尤单抗联合顺铂和多西他赛新辅助治疗2周期,术后接受度伐利尤单抗单药或联合顺铂和多西他赛辅助治疗。患者出院后,前半年每1~2个月复查1次,之后每3~6个月复查1次。主要观察指标为病理缓解率;次要观察指标为临床应答率、无疾病生存期(disease-free survival,DFS)及总体生存期(overall survival,OS)。

结果

所有入组患者的平均年龄为(59.84±7.14)岁,其中男性18例(72.00%)、女性7例(28.00%)。主要观察指标结果表明,56%的患者达到显著病理缓解,其中24%实现完全病理缓解。次要观察指标表明,0、60%、36%和4%的患者分别实现临床完全应答、部分应答、疾病稳定和疾病进展,总体客观应答率为60%。患者1年DFS为79%,1年OS为90%。东部肿瘤协作组体力状态评分、TNM分期与DFS及OS均不相关。最常见不良事件为脱发(48%)、疲乏(40%)及恶心呕吐(36%)。其中大部分不良事件为轻度1~2级,少量为3~4级。

结论

度伐利尤单抗联合顺铂和多西他赛新辅助治疗局部晚期非小细胞肺癌患者具有较好疗效。

, authors=杨晓樽1, 李强1, 2, *, authorsList=杨晓樽, 李强, authorCompany=null, correspAuthors=李强, authorNote=

杨晓樽,主治医师,研究方向:肺部肿瘤、气管肿瘤、纵隔肿瘤的诊治。

, correspAuthorsNote=
李强,主任医师,研究方向:肺部肿瘤、气管肿瘤、纵隔肿瘤的诊治。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=DKypESNqTvFNLLq3bnmoPg==, magXml=/V0yydDZac4a1ojWotZ4/Q==, pdfUrl=null, pdf=2OYOvVMGYjLJctZ1T7EPOw==, pdfFileSize=1701175, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=R01FyE5XOVzA65T2PToRqw==, mapNumber=null, fund=null)}, authors=[Author(id=1329527133535318128, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329527133631787124, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, authorId=1329527133535318128, language=EN, stringName=Xiaozun YANG, firstName=Xiaozun, middleName=null, lastName=YANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Thoracic Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Chengdu 610000, Sichuan Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329527133757616247, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, authorId=1329527133535318128, language=CN, stringName=杨晓樽, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.四川省肿瘤医院·研究所胸外科,四川省癌症防治中心,四川 成都 610000, bio={"content":"

杨晓樽,主治医师,研究方向:肺部肿瘤、气管肿瘤、纵隔肿瘤的诊治。

"}, bioImg=null, bioContent=

杨晓樽,主治医师,研究方向:肺部肿瘤、气管肿瘤、纵隔肿瘤的诊治。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329527133300437097, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, xref=1., ext=[AuthorCompanyExt(id=1329527133313020010, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, companyId=1329527133300437097, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Thoracic Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Chengdu 610000, Sichuan Province, China), AuthorCompanyExt(id=1329527133325602923, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, companyId=1329527133300437097, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.四川省肿瘤医院·研究所胸外科,四川省癌症防治中心,四川 成都 610000)])]), Author(id=1329527133854085241, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329527133984108668, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, authorId=1329527133854085241, language=EN, stringName=Qiang LI, firstName=Qiang, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, *, address=1.Department of Thoracic Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Chengdu 610000, Sichuan Province, China
2.School of Medicine, University of Electronic Science and Technology of China, Chengdu 610000, Sichuan Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329527134076383357, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, authorId=1329527133854085241, language=CN, stringName=李强, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, *, address=1.四川省肿瘤医院·研究所胸外科,四川省癌症防治中心,四川 成都 610000
2.电子科技大学医学院,四川 成都 610000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329527133300437097, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, xref=1., ext=[AuthorCompanyExt(id=1329527133313020010, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, companyId=1329527133300437097, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Thoracic Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Chengdu 610000, Sichuan Province, China), AuthorCompanyExt(id=1329527133325602923, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, companyId=1329527133300437097, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.四川省肿瘤医院·研究所胸外科,四川省癌症防治中心,四川 成都 610000)]), AuthorCompany(id=1329527133438849132, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, xref=2., ext=[AuthorCompanyExt(id=1329527133447237741, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, companyId=1329527133438849132, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.School of Medicine, University of Electronic Science and Technology of China, Chengdu 610000, Sichuan Province, China), AuthorCompanyExt(id=1329527133451432046, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, companyId=1329527133438849132, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.电子科技大学医学院,四川 成都 610000)])])], keywords=[Keyword(id=1329527134269321343, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, language=EN, orderNo=1, keyword=durvalumab), Keyword(id=1329527134349013120, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, language=EN, orderNo=2, keyword=cisplatin and docetaxel), Keyword(id=1329527134424510593, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, language=EN, orderNo=3, keyword=neoadjuvant therapy), Keyword(id=1329527134537756802, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, language=EN, orderNo=4, keyword=locally advanced non-small cell lung cancer), Keyword(id=1329527134625837189, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, language=EN, orderNo=5, keyword=efficacy), Keyword(id=1329527134722306182, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, language=EN, orderNo=6, keyword=safety), Keyword(id=1329527134797803655, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, language=CN, orderNo=1, keyword=度伐利尤单抗), Keyword(id=1329527136429387912, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, language=CN, orderNo=2, keyword=顺铂), Keyword(id=1329527136513273993, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, language=CN, orderNo=3, keyword=多西他赛), Keyword(id=1329527136618131596, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, language=CN, orderNo=4, keyword=新辅助治疗), Keyword(id=1329527136710406285, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, language=CN, orderNo=5, keyword=局部晚期非小细胞肺癌), Keyword(id=1329527136806875278, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, language=CN, orderNo=6, keyword=疗效)], refs=[Reference(id=1329527136915927183, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Hanna CR, O'Cathail SM, Graham JS, et al. Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phaseⅡtrial (PRIME-RT)[J]. Radiat Oncol, 2021, 16(1): 1-9., articleTitle=null, refAbstract=null), Reference(id=1329527137020784785, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Young MH, Pietz G, Whalen E, et al. Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma[J]. Sci Rep, 2021, 11(1): 16460., articleTitle=null, refAbstract=null), Reference(id=1329527137113059474, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Raimondi A, Palermo F, Prisciandaro M, et al. TremelImumab and durvalumab combination for the non-operative management (NOM) of microsatellite instability (MSI)-high resectable gastric or gastroesophageal junction cancer: The multicentre, single-arm, multi-cohort, phaseⅡINFINITY study[J]. Cancers (Basel), 2021, 13(11): 2839., articleTitle=null, refAbstract=null), Reference(id=1329527137180168339, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Powles T, Carroll D, Chowdhury S, et al. An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer[J]. Nat Med, 2021, 27(5): 793-801., articleTitle=null, refAbstract=null), Reference(id=1329527137251471508, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249., articleTitle=null, refAbstract=null), Reference(id=1329527137339551894, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Clark SB, Alsubait S. Non small cell lung cancer[M]. Treasure Island: StatPearls, 2021., articleTitle=null, refAbstract=null), Reference(id=1329527137456992408, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Faivre-Finn C, Vicente D, Kurata T, et al. Four-year survival with durvalumab after chemoradiotherapy in stageⅢNSCLC - an update from the PACIFIC trial[J]. J Thorac Oncol, 2021, 16(5): 860-867., articleTitle=null, refAbstract=null), Reference(id=1329527137549267097, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Socinski MA, Özgüroğlu M, Villegas A, et al. Durvalumab after concurrent chemoradiotherapy in elderly patients with unresectable stageⅢnon-small-cell lung cancer (PACIFIC)[J]. Clin Lung Cancer, 2021, 377(20): 1919-1929., articleTitle=null, refAbstract=null), Reference(id=1329527137624764570, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Landman Y, Jacobi O, Kurman N, et al. Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer[J]. Oncoimmunology, 2021, 10(1): 1959979., articleTitle=null, refAbstract=null), Reference(id=1329527137721233563, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Garon EB, Cho BC, Reinmuth N, et al. Patient-reported outcomes with durvalumab with or without tremelimumab versus standard chemotherapy as first-line treatment of metastatic non-small-cell lung cancer (MYSTIC)[J]. Clin Lung Cancer, 2021, 22(4): 301-312., articleTitle=null, refAbstract=null), Reference(id=1329527137800925342, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Altorki NK, McGraw TE, Borczuk AC, et al. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial[J]. Lancet Oncol, 2021, 22(6): 824-835., articleTitle=null, refAbstract=null), Reference(id=1329527137889005727, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Rothschild SI, Zippelius A, Eboulet EI, et al. SAKK 16/14: Durvalumab in addition to neoadjuvant chemotherapy in patients with stageⅢA(N2) non-small-cell lung cancer-a multicenter single-arm phaseⅡtrial[J]. J Clin Oncol, 2021, 39(26): 2872-2880., articleTitle=null, refAbstract=null), Reference(id=1329527137977086113, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247., articleTitle=null, refAbstract=null), Reference(id=1329527138065166499, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Hellmann MD, Chaft JE, William WN Jr, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint[J]. Lancet Oncol, 2014, 15(1): e42-e50., articleTitle=null, refAbstract=null), Reference(id=1329527138153246884, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Travis WD, Dacic S, Wistuba I, et al. IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy[J]. J Thorac Oncol, 2020, 15(5): 709-740., articleTitle=null, refAbstract=null), Reference(id=1329527138241327269, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Syed YY. Durvalumab: first global approval[J]. Drugs, 2017, 77(12): 1369-1376., articleTitle=null, refAbstract=null), Reference(id=1329527138367156390, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Leighl NB, Redman MW, Rizvi N, et al. PhaseⅡstudy of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stageⅣsquamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)[J]. J Immunother Cancer, 2021, 9(8): e002973., articleTitle=null, refAbstract=null), Reference(id=1329527138455236777, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Antill Y, et al. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial[J]. J Immunother Cancer, 2021, 9(6): e002255., articleTitle=null, refAbstract=null), Reference(id=1329527138547511466, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Marandino L, Raggi D, Calareso G, et al. Cabozantinib plus durvalumab in patients with advanced urothelial carcinoma after platinum chemotherapy: safety and preliminary activity of the open-label, single-arm, phase 2 ARCADIA trial[J]. Clin Genitourin Cancer, 2021, 19(5): 457-465., articleTitle=null, refAbstract=null), Reference(id=1329527138643980460, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Ribrag V, Lee ST, Rizzieri D, et al. a phase 1b study to evaluate the safety and efficacy of durvalumab in combination with tremelimumab or danvatirsen in patients with relapsed or refractory diffuse large B-cell lymphoma[J]. Clin Lymphoma Myeloma Leuk, 2021, 21(5): 309-317., articleTitle=null, refAbstract=null), Reference(id=1329527138862084270, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Loibl S, Untch M, Burchardi N, et al. A randomised phaseⅡstudy investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study[J]. Ann Oncol, 2019, 30(8): 1279-1288., articleTitle=null, refAbstract=null), Reference(id=1329527138962747567, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Kanikarla Marie P, Haymaker C, Parra ER, et al. Pilot clinical trial of perioperative durvalumab and tremelimumab in the treatment of resectable colorectal cancer liver metastases[J]. Clin Cancer Res, 2021, 27(11): 3039-3049., articleTitle=null, refAbstract=null), Reference(id=1329527139055022256, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Thibault C, Elaidi R, Vano YA, et al. Open-label phaseⅡto evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO[J]. Bull Cancer, 2020, 107(5S): eS8-eS15., articleTitle=null, refAbstract=null), Reference(id=1329527139155685553, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Lee JY, Kim JW, Lim MC, et al. A phaseⅡstudy of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D[J]. J Gynecol Oncol, 2019, 30(6): e112., articleTitle=null, refAbstract=null), Reference(id=1329527139239571636, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Zheng Y, Zhu W, Huang X, et al. Neoadjuvant immunotherapy combined with chemotherapy for locally advanced squamous cell lung carcinoma: a case report and literature review[J]. Open Life Sci, 2021, 16(1): 838-844., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1329527133300437097, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, xref=1., ext=[AuthorCompanyExt(id=1329527133313020010, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, companyId=1329527133300437097, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Thoracic Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Chengdu 610000, Sichuan Province, China), AuthorCompanyExt(id=1329527133325602923, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, companyId=1329527133300437097, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.四川省肿瘤医院·研究所胸外科,四川省癌症防治中心,四川 成都 610000)]), AuthorCompany(id=1329527133438849132, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, xref=2., ext=[AuthorCompanyExt(id=1329527133447237741, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, companyId=1329527133438849132, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.School of Medicine, University of Electronic Science and Technology of China, Chengdu 610000, Sichuan Province, China), AuthorCompanyExt(id=1329527133451432046, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, companyId=1329527133438849132, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.电子科技大学医学院,四川 成都 610000)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2024.05.011, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2024.05.011, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2024.05.011, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2024.05.011, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1715270400000, fullTextJson=null, articleText=null, reference=null)
收藏切换
度伐利尤单抗联合顺铂和多西他赛新辅助治疗局部晚期非小细胞肺癌的疗效评估
杨晓樽 1 , 李强 1, 2, *
世界临床药物 | 研究论文 2024,45(5): 514-520
收起
收藏切换
世界临床药物 |研究论文 2024 , 45 (5) : 514 -520
度伐利尤单抗联合顺铂和多西他赛新辅助治疗局部晚期非小细胞肺癌的疗效评估
全屏
[Author(id=1329527133535318128, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329527133631787124, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, authorId=1329527133535318128, language=EN, stringName=Xiaozun YANG, firstName=Xiaozun, middleName=null, lastName=YANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Thoracic Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Chengdu 610000, Sichuan Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329527133757616247, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, authorId=1329527133535318128, language=CN, stringName=杨晓樽, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.四川省肿瘤医院·研究所胸外科,四川省癌症防治中心,四川 成都 610000, bio={"content":"

杨晓樽,主治医师,研究方向:肺部肿瘤、气管肿瘤、纵隔肿瘤的诊治。

"}, bioImg=null, bioContent=

杨晓樽,主治医师,研究方向:肺部肿瘤、气管肿瘤、纵隔肿瘤的诊治。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329527133300437097, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, xref=1., ext=[AuthorCompanyExt(id=1329527133313020010, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, companyId=1329527133300437097, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Thoracic Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Chengdu 610000, Sichuan Province, China), AuthorCompanyExt(id=1329527133325602923, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, companyId=1329527133300437097, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.四川省肿瘤医院·研究所胸外科,四川省癌症防治中心,四川 成都 610000)])]), Author(id=1329527133854085241, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329527133984108668, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, authorId=1329527133854085241, language=EN, stringName=Qiang LI, firstName=Qiang, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, *, address=1.Department of Thoracic Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Chengdu 610000, Sichuan Province, China
2.School of Medicine, University of Electronic Science and Technology of China, Chengdu 610000, Sichuan Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329527134076383357, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, authorId=1329527133854085241, language=CN, stringName=李强, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, *, address=1.四川省肿瘤医院·研究所胸外科,四川省癌症防治中心,四川 成都 610000
2.电子科技大学医学院,四川 成都 610000, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329527133300437097, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, xref=1., ext=[AuthorCompanyExt(id=1329527133313020010, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, companyId=1329527133300437097, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Thoracic Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Chengdu 610000, Sichuan Province, China), AuthorCompanyExt(id=1329527133325602923, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, companyId=1329527133300437097, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.四川省肿瘤医院·研究所胸外科,四川省癌症防治中心,四川 成都 610000)]), AuthorCompany(id=1329527133438849132, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, xref=2., ext=[AuthorCompanyExt(id=1329527133447237741, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, companyId=1329527133438849132, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.School of Medicine, University of Electronic Science and Technology of China, Chengdu 610000, Sichuan Province, China), AuthorCompanyExt(id=1329527133451432046, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329527132511907939, companyId=1329527133438849132, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.电子科技大学医学院,四川 成都 610000)])])]
杨晓樽1, 李强1, 2, *
作者信息
  • 1.四川省肿瘤医院·研究所胸外科,四川省癌症防治中心,四川 成都 610000
  • 2.电子科技大学医学院,四川 成都 610000
通讯作者:
李强,主任医师,研究方向:肺部肿瘤、气管肿瘤、纵隔肿瘤的诊治。
作者简介:

杨晓樽,主治医师,研究方向:肺部肿瘤、气管肿瘤、纵隔肿瘤的诊治。

Efficacy of durvalumab combined with cisplatin and docetaxel as neoadjuvant therapy in the treatment of locally advanced non-small cell lung cancer patients
Xiaozun YANG1, Qiang LI1, 2, *
Affiliations
  • 1.Department of Thoracic Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Chengdu 610000, Sichuan Province, China
  • 2.School of Medicine, University of Electronic Science and Technology of China, Chengdu 610000, Sichuan Province, China
出版时间: 2024-05-10 doi: 10.13683/j.wph.2024.05.011
文章导航
收藏切换
目的

探索度伐利尤单抗联合顺铂和多西他赛新辅助治疗局部晚期非小细胞肺癌的疗效与安全性。

方法

本前瞻性、单臂临床研究纳入25例2020年1月至2021年3月局部晚期非小细胞肺癌患者,术前接受度伐利尤单抗联合顺铂和多西他赛新辅助治疗2周期,术后接受度伐利尤单抗单药或联合顺铂和多西他赛辅助治疗。患者出院后,前半年每1~2个月复查1次,之后每3~6个月复查1次。主要观察指标为病理缓解率;次要观察指标为临床应答率、无疾病生存期(disease-free survival,DFS)及总体生存期(overall survival,OS)。

结果

所有入组患者的平均年龄为(59.84±7.14)岁,其中男性18例(72.00%)、女性7例(28.00%)。主要观察指标结果表明,56%的患者达到显著病理缓解,其中24%实现完全病理缓解。次要观察指标表明,0、60%、36%和4%的患者分别实现临床完全应答、部分应答、疾病稳定和疾病进展,总体客观应答率为60%。患者1年DFS为79%,1年OS为90%。东部肿瘤协作组体力状态评分、TNM分期与DFS及OS均不相关。最常见不良事件为脱发(48%)、疲乏(40%)及恶心呕吐(36%)。其中大部分不良事件为轻度1~2级,少量为3~4级。

结论

度伐利尤单抗联合顺铂和多西他赛新辅助治疗局部晚期非小细胞肺癌患者具有较好疗效。

度伐利尤单抗  /  顺铂  /  多西他赛  /  新辅助治疗  /  局部晚期非小细胞肺癌  /  疗效
Objective

To explore the efficacy and safety of durvalumab combined with cisplatin and docetaxel as neoadjuvant therapy in the treatment of locally advanced non-small cell lung cancer (NSCLC) patients.

Methods

This prospective, single-arm clinical study included twenty-five patients with locally advanced NSCLC from January 2020 to March 2021 who received durvalumab combined with cisplatin and docetaxel neoadjuvant therapy for 2 cycles before surgery. Then they received durvalumab monotherapy or combined with cisplatin and docetaxel adjuvant therapy after surgery. After discharge, patients were followed up every 1 to 2 months for the first six months and every 3 to 6 months thereafter. The primary outcome was pathological remission rate. Secondary outcome measures were clinical response rate, disease-free survival (DFS), and overall survival (OS).

Results

The mean age of all enrolled patients was (59.84±7.14) years, including 18 males (72.00%) and 7 females (28.00%). The primary outcome indicated that 56% patients achieved significant pathological response, among which 24% achieved complete pathological response. The secondary outcome showed that 0, 60%, 36% and 4% patients achieved clinical complete response, partial response, disease stability and disease progression, and the overall objective response rate was 60%. The 1-year DFS was 79%, and the 1-year OS was 90%. There was no correlation of Eastern Cooperative Oncology Group performance status and TNM stage with DFS or OS. Besides, The most common adverse events were alopecia (48%), fatigue (40%), nausea and vomiting (36%). Most of the adverse events were at grade 1 to 2, only a few were at grade 3 to 4.

Conclusion

Durvalumab combined with cisplatin and docetaxel exhibits good efficacy profile as neoadjuvant therapy in locally advanced NSCLC patients.

durvalumab  /  cisplatin and docetaxel  /  neoadjuvant therapy  /  locally advanced non-small cell lung cancer  /  efficacy  /  safety
杨晓樽, 李强. 度伐利尤单抗联合顺铂和多西他赛新辅助治疗局部晚期非小细胞肺癌的疗效评估. 世界临床药物, 2024 , 45 (5) : 514 -520 . DOI: 10.13683/j.wph.2024.05.011
Xiaozun YANG, Qiang LI. Efficacy of durvalumab combined with cisplatin and docetaxel as neoadjuvant therapy in the treatment of locally advanced non-small cell lung cancer patients[J]. World Clinical Drug, 2024 , 45 (5) : 514 -520 . DOI: 10.13683/j.wph.2024.05.011

参考文献 引证文献
排序方式:
[1]
Hanna CR, O'Cathail SM, Graham JS, et al. Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phaseⅡtrial (PRIME-RT)[J]. Radiat Oncol, 2021, 16(1): 1-9.
[2]
Young MH, Pietz G, Whalen E, et al. Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma[J]. Sci Rep, 2021, 11(1): 16460.
[3]
Raimondi A, Palermo F, Prisciandaro M, et al. TremelImumab and durvalumab combination for the non-operative management (NOM) of microsatellite instability (MSI)-high resectable gastric or gastroesophageal junction cancer: The multicentre, single-arm, multi-cohort, phaseⅡINFINITY study[J]. Cancers (Basel), 2021, 13(11): 2839.
[4]
Powles T, Carroll D, Chowdhury S, et al. An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer[J]. Nat Med, 2021, 27(5): 793-801.
[5]
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[6]
Clark SB, Alsubait S. Non small cell lung cancer[M]. Treasure Island: StatPearls, 2021.
[7]
Faivre-Finn C, Vicente D, Kurata T, et al. Four-year survival with durvalumab after chemoradiotherapy in stageⅢNSCLC - an update from the PACIFIC trial[J]. J Thorac Oncol, 2021, 16(5): 860-867.
[8]
Socinski MA, Özgüroğlu M, Villegas A, et al. Durvalumab after concurrent chemoradiotherapy in elderly patients with unresectable stageⅢnon-small-cell lung cancer (PACIFIC)[J]. Clin Lung Cancer, 2021, 377(20): 1919-1929.
[9]
Landman Y, Jacobi O, Kurman N, et al. Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer[J]. Oncoimmunology, 2021, 10(1): 1959979.
[10]
Garon EB, Cho BC, Reinmuth N, et al. Patient-reported outcomes with durvalumab with or without tremelimumab versus standard chemotherapy as first-line treatment of metastatic non-small-cell lung cancer (MYSTIC)[J]. Clin Lung Cancer, 2021, 22(4): 301-312.
[11]
Altorki NK, McGraw TE, Borczuk AC, et al. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial[J]. Lancet Oncol, 2021, 22(6): 824-835.
[12]
Rothschild SI, Zippelius A, Eboulet EI, et al. SAKK 16/14: Durvalumab in addition to neoadjuvant chemotherapy in patients with stageⅢA(N2) non-small-cell lung cancer-a multicenter single-arm phaseⅡtrial[J]. J Clin Oncol, 2021, 39(26): 2872-2880.
[13]
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247.
[14]
Hellmann MD, Chaft JE, William WN Jr, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint[J]. Lancet Oncol, 2014, 15(1): e42-e50.
[15]
Travis WD, Dacic S, Wistuba I, et al. IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy[J]. J Thorac Oncol, 2020, 15(5): 709-740.
[16]
Syed YY. Durvalumab: first global approval[J]. Drugs, 2017, 77(12): 1369-1376.
[17]
Leighl NB, Redman MW, Rizvi N, et al. PhaseⅡstudy of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stageⅣsquamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)[J]. J Immunother Cancer, 2021, 9(8): e002973.
[18]
Antill Y, et al. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial[J]. J Immunother Cancer, 2021, 9(6): e002255.
[19]
Marandino L, Raggi D, Calareso G, et al. Cabozantinib plus durvalumab in patients with advanced urothelial carcinoma after platinum chemotherapy: safety and preliminary activity of the open-label, single-arm, phase 2 ARCADIA trial[J]. Clin Genitourin Cancer, 2021, 19(5): 457-465.
[20]
Ribrag V, Lee ST, Rizzieri D, et al. a phase 1b study to evaluate the safety and efficacy of durvalumab in combination with tremelimumab or danvatirsen in patients with relapsed or refractory diffuse large B-cell lymphoma[J]. Clin Lymphoma Myeloma Leuk, 2021, 21(5): 309-317.
[21]
Loibl S, Untch M, Burchardi N, et al. A randomised phaseⅡstudy investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study[J]. Ann Oncol, 2019, 30(8): 1279-1288.
[22]
Kanikarla Marie P, Haymaker C, Parra ER, et al. Pilot clinical trial of perioperative durvalumab and tremelimumab in the treatment of resectable colorectal cancer liver metastases[J]. Clin Cancer Res, 2021, 27(11): 3039-3049.
[23]
Thibault C, Elaidi R, Vano YA, et al. Open-label phaseⅡto evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO[J]. Bull Cancer, 2020, 107(5S): eS8-eS15.
[24]
Lee JY, Kim JW, Lim MC, et al. A phaseⅡstudy of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D[J]. J Gynecol Oncol, 2019, 30(6): e112.
[25]
Zheng Y, Zhu W, Huang X, et al. Neoadjuvant immunotherapy combined with chemotherapy for locally advanced squamous cell lung carcinoma: a case report and literature review[J]. Open Life Sci, 2021, 16(1): 838-844.
2024年第45卷第5期
21
5
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2024.05.011
  • 接收时间:2023-10-15
  • 首发时间:2026-11-17
  • 出版时间:2024-05-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2023-10-15
基金
作者信息
    1.四川省肿瘤医院·研究所胸外科,四川省癌症防治中心,四川 成都 610000
    2.电子科技大学医学院,四川 成都 610000

通讯作者:

李强,主任医师,研究方向:肺部肿瘤、气管肿瘤、纵隔肿瘤的诊治。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2024.05.011
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏